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– Adult (AIM - A) were the most commonly used disease specific instruments used
in clinical trials. Both, AAQoL and AIM-A have demonstrated good construct valid-
ity, responsiveness to changes in ADHD symptom severity, and internal consis-
tency of 0.93 and 0.83, respectively. Generic instruments like the SF-36 and the
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used in 3
RCTs to evaluate QoL. The Q-LES-Q has also demonstrated good internal consis-
tency of 0.88 among adults with ADHD. CONCLUSIONS: Given the strong psycho-
metric properties and ability to discriminate between patients with varying de-
grees of symptom severity, the AAQoL and AIM-A justify their use in clinical
practice. These scales can be used in conjunction with diagnostic scales like the
Conner’s Adult ADHD Rating Scale in making effective treatment decisions on a per
patient basis. Future efforts need to focus on increasing the awareness and uptake
of these scales in regular clinical practice.
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OBJECTIVES: Recent research on biomarkers for Alzheimer’s disease (AD) suggests
possibilities for earlier diagnosis and treatment. Existing treatments, however, fo-
cus on symptomatic relief, and controlled clinical trials have shown little effect on
disease progression and time to institutionalization. This study assesses effects of
treatment timing on risk of institutionalization of AD patients in a real-world
setting. METHODS: Retrospective analysis of administrative claims data for New
Jersey Medicaid patients (1997-2009). Patients were included if they had 2 claims
with AD diagnosis, or 1 claim and a prescription for AD treatment (donepezil,
galantamine, memantine, rivastigmine, or tacrine); N5,790. The index date was
defined as the earliest claim with any dementia/memory loss diagnosis (ICD-9-CM:
290, 291.2, 292.82, 294, 331, 780.93), possibly preceding AD diagnosis. Institutional-
ization was defined as 90-day stay in a long-term care facility. The effect of
treatment on institutionalization risk was estimated at the patient-quarter level
using logistic regression with repeated measures, controlling for a quadratic time-
trend and baseline characteristics. The model was used to predict the conditional
probability (hazard rate) of institutionalization by prior treatment and quarter fol-
lowing index diagnosis. In turn, predicted hazard curves were constructed for dif-
ferent treatment scenarios. RESULTS: Median interval to treatment was 7 quarters
(21 months) from index date diagnosis. Treatment in prior quarters reduced insti-
tutionalization risk [OR 0.88, CI 0.78-0.99]. Older age on index and AD diagnosis in
prior quarters increased institutionalization risk. The predicted hazard curves im-
ply that initiating treatment at the earliest observed onset of memory-loss symp-
toms could delay institutionalization by 4 months, compared with median ob-
served initiation. CONCLUSIONS: Treatment in earlier periods is associated with a
small statistically significant delay in time to institutionalization among AD pa-
tients, possibly due to reduction in symptom burden. These findings may be espe-
cially relevant in light of new criteria facilitating earlier diagnosis of AD.
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A REAL WORLD EVALUATION OF THE TIME ASSOCIATED WITH
ADMINISTRATION OF A SINGLE EPISODE OF TREATMENT IN PATIENTS WITH
HEREDITARY ANGIOEDEMA (HAE) IN THE HOME AND HOSPITAL
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OBJECTIVES: To describe the time associated with administration of icatibant and
C1 esterase inhibitor concentrate (C1) in patients with HAE when given in hospital
and self administered at home. METHODS: A local service evaluation was con-
ducted in a single UK hospital Trust between January and May 2011. Direct time and
motion observation was used to measure the time associated with set-up, admin-
istration and post-administration activities for icatibant and C1 in hospital. Times
associated with home administration were reported by the patient or care-giver.
The product and dose received were recorded. As dose of C1 is body weight depen-
dent, the time for administration of 1000U was also recorded for comparison.
RESULTS: Fifteen HAE episodes (hospital: 3 C1, 0 icatibant and home: 9 C1 and 3
icatibant) were observed in 8 patients (Hospital 3 C1: 0 icatibant, home 3 C1: 2
icatibant). Patients received 30mg icatibant and between 1000U-1,500U C1. Mean
set-up time (min:sec): Home - C1 15:47 v icatibant 1:43; Hospital - C1 20:44. Mean
administration time (min:sec): Home - C1 Total dose 7:28, C1 1000U 5:32 versus
icatibant 2:06; Hospital - C1 Total dose 12:18, C1. 1000U 9:54. Mean time post ad-
ministration (min:sec): Home - C1 6:30 v icatibant 1:34; Hospital - C1 4:36. Mean
total time (min:sec): Home - C1 Total dose 29:46; C1 1000U 27:50 v icatibant 5:23;
Hospital - C1 Total dose 37:38; C1 1000U 35:14. CONCLUSIONS: Total time associ-
ated with administration of therapy for HAE is shorter for icatibant than C1 in the
home setting. Further the total time associated with administration of either ther-
apy at home is less than C1 in hospital. Therefore encouraging home administra-
tion and offering choice of therapies may offer significant NHS resource use savings
and patient preference benefits in appropriate patients.
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OBJECTIVES: Apply a MCDA-based model to support and streamline policy and
clinical decisionmaking for growth hormone (GH) therapy in patients with Prader-
Willi syndrome (PWS), a rare genetic disorder with serious long-term conse-
quences including short stature and morbid obesity. METHODS: An extensive lit-
erature review was performed to identify and synthesize available evidence on GH
for PWS for 19 criteria of the EVIDEM framework using a standardized methodol-
ogy. Evidence tables, quality assessment of studies, and synthesis of data by crite-
rion, were validated by a wide range of experts using an interactive web site. The
framework was used to develop CPG questions and structure development of in-
ternational recommendations during a consensus workshop. RESULTS: The web
site provided transparent access to synthesized evidence at 3 levels of detail for 13
scientific criteria of the EVIDEM MCDA model including: disease severity, size of
population, therapeutic context and unmet needs, treatment outcomes (efficacy/
effectiveness, safety, patient-reported outcomes), type of treatment benefit at pop-
ulation and individual levels, and economic impact on medical and non-medical
expenditures. Quality assessments of studies were hyperlinked to synthesized ev-
idence. Evidence for the six contextual and ethical criteria, including utility, effi-
ciency, fairness, system capacity, stakeholder pressures, and political/historical
context, was synthesized. CPG questions were developed following this format.
CONCLUSIONS: The “by criteria” web model provides a pragmatic means for sys-
tematic consideration of a wide range of criteria, seamless access to information
and development of CPGs to guide evidence-based decisions. This work will serve
to structure deliberations of a pan-Canadian taskforce to examine the conditions
for successful implementation (obstacles and facilitating factors) of evidence-
based CPG. The ultimate goal is to bridge the gap between researchers, policy
decision-making, clinical practice and patient concerns to optimize resource allo-
cation and health care system sustainability.
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OBJECTIVES: To examine utilization of Rasagiline and Selegiline, two commonly
prescribed medications for the treatment of Parkinson’s Disease (PD). METHODS:
Data for this study were obtained from the US i3 LabRx database over the time
period from January 1, 2006 through December 30, 2010. Patients were included in
the analysis if they were prescribed Rasagiline or Selegiline (with first such date
identified as the index date), were diagnosed with PD, and had continuous insur-
ance coverage from 6 months prior through 12 months post index date. Analyses
are primarily descriptive in nature.RESULTS:There were 1242 individuals included
in the study - 926 who initiated on Rasagiline and 316 who initiated on Selegiline.
Patients initiated on Rasagiline, compared to Selegiline, were significantly younger
(63.2 years vs. 65.4 years; P0.0020); less likely to have a gap in therapy for at least
60 days (0.86% v 2.85%; P0.0088; associated with a higher medication possession
ration (MPR) (0.62 vs. 0.52; P0.0001); and associated with a longer persistence of
use (259 days vs. 229 days; P0.0013). Despite the fact that Selegiline is approved
only as adjunctive use, there was no statistical significant difference in the per-
centage of patients using the medication in combination with another PD medica-
tion (75.96% vs. 73.43%; P0.3783). CONCLUSIONS: Results from this retrospective
study indicate that the two medications are both used primarily as adjunctive
medications. Furthermore, approximately 25% of patients who initiate on Selegi-
line were found to not have used other PD medications adjunctively in the 1 year
post initiation. Rasagiline use, compared to use of Selegiline, was found to be
associated with fewer gaps in therapy, a higher MPR and longer persistence in
therapy.
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OBJECTIVES: Treatment restrictions because of patient financial burden may have
unintended consequence on management of multiple sclerosis (MS). The goal was
to evaluate MS treatment compliance among patients enrolled in insurance plans
with various cost-sharing arrangements for disease modifying therapies (DMT).
METHODS: Thomson Reuters MarketScan® Commercial and Medicare databases
(January 1, 2004-December 31, 2009) were used to identify adult patients with MS
(ICD-9-CM: 340) and on DMT (claim for first DMT was the index event). Patients
were assigned to three mutually exclusive cohorts based on DMT insurance plan
cost-sharing levels: $0-, low- and high-cost-sharing. Median cost-sharing for DMTs,
standardized to 2010 US dollars, was used to determine threshold between ‘low’
and ‘high’. Medication possession ratio (MPR) and persistence (time to discontinu-
ation of DMT) were evaluated during 12-months following index. RESULTS: A total
of 14,718 patients were identified and had cost-sharing arrangements as follows: $0
cost-sharing (n1,361, 9.2%), low cost-sharing (n6,044, 41.1%) and high cost-shar-
ing (n7,313, 49.7%). Majority were female (77%) and mean age was 46.1 years.
Patients in $0 cost-sharing plans had significantly higher MPR values (0.83) than
patients in both the low cost-sharing (0.81; p0.037) and high cost-sharing plans
(0.79; p0.001). Discontinuation rates were also lower among patients in $0 cost-
sharing plans (34.1%) versus patients with any cost-sharing (35.5% for low and
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37.2% for high cost-sharing; p0.001). CONCLUSIONS: Patients in plans with no
cost-sharing have greater adherence and are less likely to discontinue treatment in
the 12-month period following DMT initiation. These results suggest that patients
with MS are sensitive to the financial costs associated with DMT and may make
treatment decisions based on this burden. Manufacturer co-pay assistance pro-
grams designed to reduce patient financial burden were not considered in this
analysis. Therefore, these results may underestimate the effects of benefit design
on medication adherence and persistence.
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OBJECTIVES: Since launch, HTA agencies from Germany, France and UK have re-
peatedly reviewed the use of Alzheimer’s disease (AD) treatments and issued rec-
ommendations, which have changed over time. The aim of this study was to un-
derstand the drivers of agency decisions and whether these too have changed over
time. METHODS: We reviewed HTA appraisals by IQWIG, HAS and NICE for three
acetylcholinesterase inhibitors (AChEI) donepezil, galantamine, rivastigmine and
memantine, an NMDA receptor antagonist from marketing authorisation to today
and identified arguments leading to recommendations. RESULTS: Between 1997
and 2002, the EMA approved donepezil, rivastigmine and galantamine for mild to
moderate AD and memantine for moderate to severe AD. We identified 2 multiple
technology assessments (MTA) and 3 single technology assessments (STA) by
IQWIG, 1 MTA and 16 STAs from HAS and 3 MTAs from NICE. Germany: IQWIG
ascribed the AChEI class a modest clinical benefit. Following two negative assess-
ments of memantine, the decision was reversed based on post-hoc analysis of
initial registration studies. France: HAS initially assigned all treatments an impor-
tant clinical added value (AMSR II) acknowledging high innovation. Later HAS re-
viewed the compounds in a new comparative setting (after withdrawal of tacrine)
and assigned only a minor clinical added value (ASMR IV). UK: NICE recommended
AChEIs in 2001, restricted their use in 2006 and in 2011 again recommended them,
while memantine received two negative recommendations followed by a positive
recommendation. The last review was based on additional data from randomized
clinical trials and the Assessment Group’s model demonstrating delay to
institutionalisation. CONCLUSIONS: The agencies revised assessments based on
post-marketing data. Differing national approaches led to different decisions:
IQWIG emphasises patient relevant benefit, HAS the clinical added value versus
similar medicinal products and NICE cost-effectiveness. Although agency deci-
sions changed, decision drivers were consistent across evaluations.
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DRUG PRESCRIPTION IN AND HOSPITALIZATION OF REFRACTORY FOCAL
EPILEPSY PATIENTS IN THE GERMAN NEUROTRANSDATA (NTD)
NEUROLOGISTS’ NETWORK – IS THERE AN UNMET NEED?
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OBJECTIVES: To quantify annual drug costs and hospitalization rates (HR) of adult
refractory focal epilepsy patients in Germany. METHODS: We retrospectively esti-
mated the annual HR and medication for refractory focal epilepsy patients based
on the NeuroTransData epilepsy database (input from 79neurologists, 34centers,
1240patients). Inclusion criteria (at least 1year of disease history; documentation
and treatment period of at least 6months; treatment with at least 1anitepileptic
drug [AED] in patient history; at least 1seizure during 6months of monitoring) led to
the identification of 70 patients. Average ambulatory daily therapy costs among all
prescribed drugs included were based on public prices (2011) considering claw-
backs and average dosing (real world setting [RWS] vs. daily defined dosing [DDD]).
HR were based on number of patients hospitalized. RESULTS: On average 2.1AEDs
per patient were prescribed, mainly generic drugs or branded drugs close to loss of
patent protection. Average daily costs per prescribed drug ranged from 0.65€ (Val-
proate) to 9.51€ (Lacosamid). Daily drug costs per patient ranged between 7.01€
(RWS) and 6.16€ (DDD). Annual total drug costs per patient were on average
2,557.44€. An ambulatory consultation rate of 2.1visits per patient within 6months
was recorded. Average HR was 44%, taking into account various reasons: 56% emer-
gency, 20% new adjustment for medication, 18% documentation of seizure, 4%
rehabilitation, 2% pre-surgical diagnostics. Mean duration was 34.9 (CI: 20.2-49.6;
median 17.8) days per patient hospitalized. Due to the potential selection bias and
the low number of analysed patients these results must be seen as indicative.
CONCLUSIONS: A 44% HR and a high average number of inpatient days (1month)
within 1year point to an unmet need for treatment optimization in refractory focal
epilepsy patients. It indicates that patients receiving combination therapy of con-
ventional drugs are often not well controlled, supporting the consideration of using
more innovative drugs.
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MULTIPLE SCLEROSIS PATIENTS IN GERMANY
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OBJECTIVES: Several disease-modifying therapies (DMTs) including IFNB-1b have
been approved for patients with multiple sclerosis (MS) to delay disease progres-
sion and reduce the incidence of relapses. Fingolimod, the first oral formulation of
DMT, was recently approved in several nations around the world including Ger-
many. This study aims to conduct a cost-minimization analysis to estimate the
cost impact of MS treatment with Fingolimod versus INFB-1b in Germany from the
societal perspective.METHODS:A Markov model is developed to follow the natural
history MS patients from time of diagnosis through disease progression and up to
20 years. MS patients receive either IFNB-1b or Fingolimod treatment but share the
same efficacy on disease progression and relapse rate due to the absence of head-
to-head comparison data. Fingolimod patients are assumed to have 10% higher
treatment adherence due to the oral formulation. In the model, DMTs costs (IFNB-
1b: €19,444/year and Fingolimod: €30,584/year) are based on AVP pharmacy retail
price, while other cost items are estimated from published literatures or local
databases. Main model outcomes include direct costs, indirect costs, and total
costs. All costs are inflated to 2010 Euros and discounted annually at 5%. RESULTS:
In the short-term analysis, Fingolimod costs additional €8,929 per patient in one
year and €29,550 per patient in 5 years compared to IFNB-1b. Long-term analysis (20
years) shows that cost savings associated with IFNB-1b is €41,593 per patient,
which mainly occurs when MS patients are still receiving treatment. The cost
advantages of IFNB-1b in the long-term analysis are attributed to its lower drug cost
(€50,342 vs. €92,873), serious adverse events management (€6.7 vs. €102.4), and
clinical monitoring (€8.8 vs. €438.2). CONCLUSIONS: Compared to Fingolimod, MS
treatment with INFB-1b leads to substantial cost savings from both societal and
payer perspectives in Germany, with similar treatment effectiveness.
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OBJECTIVES: The SF-6D and the EQ-5D are two widely used questionnaires to
generate utility scores. The objective of this study is to describe and compare
utilities derived from EQ-5D and SF-6D in Huntington’s disease population.
METHODS:We used data from Euro-HDB, a multicenter cross-sectional study con-
ducted in France, Italy, Poland and Germany. In several subpopulations, with dif-
ferent degrees of severity, we used paired-samples t-test to identify significant
differences and calculated the Pearson’s correlation between SF-6D and the EQ-5D
utilities. RESULTS: The overall sample included 278 patients: 96 from France, 32
from Gemany, 103 from Italy and 47 from Poland. For the overall population, mean
utility scores were significantly different (EQ-5D: 0.34 (sd0.446); SF-6D: 0.62
(sd0.135); p0.0001). However values were strongly correlated (r 0.79, p0.001).
This difference was also significant when considering subpopulations (as discrim-
inated with score of clinical motor scale, and depression scale), with higher values
for SF-6D. The difference between EQ-5D and SF-6D utility scores was higher in
severe population than in moderate for most of the studied criteria (severe motor
impairment: EQ-5D: 0.62; SF-6D: 0.69; moderate motor impairment: EQ-5D: 0.00;
SF-6D: 0.51). The SF-6D scores distribution was found to be approximately normal
whereas the EQ-5D distribution was negatively skewed. CONCLUSIONS: In our
study, EQ-5D tends to generate lower scores in all Huntington’s disease subpopu-
lations. EQ-5D appears to be more sensitive than SF-6D. The choice of utility mea-
sure is likely to have a strong impact on incremental cost-effectiveness ratios of
interventions slowing the progression of Huntington’s disease.
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VERSION OF THE FATIGUE SEVERITY SCALE (FSS)
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OBJECTIVES: The aim was to perform a cross-cultural adaptation and validation of
the Fatigue Severity Scale (FSS) for use in Brazilian patients with myopathy and
who complains of precocious muscular fatigue. METHODS: The FSS presents nine
items measured on a Likert scale ranging from 1 (completely disagree) to 7 (com-
pletely agree), where higher scores indicate higher level of fatigue. The process of
cross-cultural adaptation included: two independent translations for Portuguese
spoken in Brazil; the development of a consensual translated version; application
in a pilot group (n14) of patients with myopathy; evaluation by an expert com-
mittee for content validation; a back-translation by one bilingual translator whose
native tongue was English, but who was fluent in Brazilian Portuguese. The two
English versions (original and back translated) were analyzed by two of the authors
and a final Brazilian version was obtained. Twenty one patients with muscular
disease following at the outpatient clinic from a University Hospital answered the
Brazilian version of the FSS, the visual analogue scale (VAS) and the Chalder fatigue
questionnaire (CFQ). The following analyses were performed: exploratory factorial
analysis; internal consistency (Cronbach’s alpha); construct validity through of the
correlation with VAS and CFQ (physical and mental components). RESULTS: The
FSS scale obtained in the process of cross cultural adaptation was comprehensible
to individuals in the pilot population. The twenty one patients who participate in
the validation process were aged 21 to 65 years. The exploratory factor analysis
determined one factor, as the original version. Reliability analysis indicated satis-
factory internal consistency (0.93). Construct validity of the FSS (total score) with
VAS and CFQ demonstrated moderate correlations (0.60 and physical0.56, respec-
tively). The FSS didn=t correlate with mental component of the CFQ (0.31).
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